SLDB
HEALTHCARESolid Biosciences Inc
$7.20+0.30 (+4.35%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SLDB Today?
No stock-specific AI insight has been generated for SLDB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.41$8.87
$7.20
Fundamentals
Market Cap$696M
P/E Ratio—
EPS$-1.99
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.3M
Avg Volume (10D)—
Shares Outstanding98.4M
SLDB News
20 articles- Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyYahoo Finance·May 7, 2026
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell TherapyYahoo Finance·Apr 30, 2026
- Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular DystrophyYahoo Finance·Apr 28, 2026
- Solid Biosciences to Participate at Upcoming Investor ConferencesYahoo Finance·Apr 7, 2026
- Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 19, 2026
- Solid Biosciences says interim results reinforce confidence in SGT-003 potentialYahoo Finance·Mar 12, 2026
- Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical RisksMotley Fool·Mar 11, 2026
- Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE TrialYahoo Finance·Mar 11, 2026
- Solid Biosciences Announces Oversubscribed $240 Million Private PlacementYahoo Finance·Mar 6, 2026
- Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceYahoo Finance·Mar 6, 2026
- Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia UpdateMarketbeat·Feb 15, 2026
- Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular DystrophyYahoo Finance·Feb 9, 2026
- Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 6, 2026
- Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?Yahoo Finance·Jan 16, 2026
- JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy successPharmaceutical-technology·Jan 15, 2026
- Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101Yahoo Finance·Jan 13, 2026
- Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s AtaxiaYahoo Finance·Jan 12, 2026
- Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s AtaxiaYahoo Finance·Jan 12, 2026
- Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 6, 2026
All 20 articles loaded
Price Data
Open$7.13
Previous Close$6.90
Day High$7.54
Day Low$7.11
52 Week High$8.87
52 Week Low$2.41
52-Week Range
$2.41$8.87
$7.20
Fundamentals
Market Cap$696M
P/E Ratio—
EPS$-1.99
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.3M
Avg Volume (10D)—
Shares Outstanding98.4M
About Solid Biosciences Inc
Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—